Michael Skynner News Today

Bicycle Therapeutics plc (NASDAQ:BCYC – Free Report) CTO Michael Skynner sold 451 shares of the firm’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $25.10, for a total transaction of $11,320.10. Following the sale, the chief technology officer now owns 70,924 shares of the […]

Bicycle Therapeutics plc (NASDAQ:BCYC – Free Report) CTO Michael Skynner sold 451 shares of the business’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $25.10, for a total transaction of $11,320.10. Following the completion of the sale, the chief technology officer now owns 70,924 shares in […]

Scientists at the University of Liverpool have been collaborating across different disciplines over the past three years to identify and help translate COVID-19 antiviral treatments. A recently published paper details how academics at the University work...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced

Continued clinical progress across pipeline of Bicycle Toxin Conjugates (BTCs) and Bicycle tumor-targeted immune cell agonists (Bicycle TICAs) Cash of $438.7 million at December 31, 2021 expected to